Technical Analysis for MRSN - Mersana Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical MRSN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 1.05% | |
| Wide Bands | Range Expansion | 1.05% | |
| Down 3 Days in a Row | Weakness | 1.05% | |
| Oversold Stochastic | Weakness | 1.05% | |
| Wide Bands | Range Expansion | -0.22% | |
| 180 Bearish Setup | Bearish Swing Setup | -4.84% | |
| Multiple of Ten Bearish | Other | -4.84% | |
| Wide Bands | Range Expansion | -4.84% | |
| Oversold Stochastic | Weakness | -4.84% | |
| Slingshot Bearish | Bearish Swing Setup | -7.58% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakdown | about 3 hours ago | |
| Down 3% | about 4 hours ago | |
| Fell Below Previous Day's Low | about 5 hours ago | |
| Down 2 % | about 5 hours ago | |
| Down 1% | about 5 hours ago |
Get a Trading Assistant
- Earnings date: 11/09/2020
Mersana Therapeutics, Inc. Description
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Development Immunology Cancers Monoclonal Antibodies Chemotherapy Antibody Drug Conjugates Linker Synaffix
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.09 |
| 52 Week Low | 4.12 |
| Average Volume | 1,172,944 |
| 200-Day Moving Average | 20.73 |
| 50-Day Moving Average | 21.43 |
| 20-Day Moving Average | 20.81 |
| 10-Day Moving Average | 19.02 |
| Average True Range | 1.32 |
| ADX | 20.72 |
| +DI | 16.36 |
| -DI | 30.79 |
| Chandelier Exit (Long, 3 ATRs ) | 20.43 |
| Chandelier Exit (Short, 3 ATRs ) | 21.34 |
| Upper Bollinger Band | 24.81 |
| Lower Bollinger Band | 16.80 |
| Percent B (%b) | 0.16 |
| BandWidth | 38.47 |
| MACD Line | -0.85 |
| MACD Signal Line | -0.60 |
| MACD Histogram | -0.2483 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 20.03 | ||||
| Resistance 3 (R3) | 20.09 | 19.50 | 19.70 | ||
| Resistance 2 (R2) | 19.50 | 19.01 | 19.47 | 19.59 | |
| Resistance 1 (R1) | 18.80 | 18.71 | 18.51 | 18.74 | 19.49 |
| Pivot Point | 18.21 | 18.21 | 18.07 | 18.18 | 18.21 |
| Support 1 (S1) | 17.51 | 17.72 | 17.22 | 17.45 | 16.69 |
| Support 2 (S2) | 16.92 | 17.42 | 16.89 | 16.59 | |
| Support 3 (S3) | 16.22 | 16.92 | 16.48 | ||
| Support 4 (S4) | 16.16 |
